Streetbeat News

Price Targets

DKNG

Argus Research analyst John Eade maintains a Buy rating on DraftKings (NASDAQ:DKNG) and raises the price target from $30 to $34.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 5:01 pm

RIVN

DA Davidson analyst Michael Shlisky maintains a Neutral rating on Rivian Automotive (NASDAQ:RIVN) and raises the price target from $18 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 5:00 pm

GBCI

Over the past 3 months, 5 analysts have published their opinion on Glacier Bancorp (NYSE:GBCI) stock. The company has an average price target of $34.8, a decrease of 5.95% from the previous average price target of $37.00. The ratings include 2 bullish, 1 somewhat bullish, and 2 indifferent.

Portfolio Pulse from Benzinga Insights

August 10, 2023 | 5:00 pm

ISPO

Cantor Fitzgerald analyst Brett Knoblauch has maintained an Overweight rating on Inspirato (NASDAQ:ISPO) but lowered the price target from $2.9 to $2.4.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 5:00 pm

DNLI

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a price target of $85.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:59 pm

LYFT

DA Davidson analyst Tom White maintains a Neutral rating on Lyft and raises the price target from $9.75 to $11.5.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:58 pm

ADMA

Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on ADMA Biologics and raises the price target from $5 to $6.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:58 pm

HYLN

Cantor Fitzgerald analyst Andres Sheppard has maintained a Neutral rating on Hyliion Holdings (NYSE:HYLN) and lowered the price target from $3 to $2.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 4:58 pm

GBCI

DA Davidson analyst Jeff Rulis maintains a 'Buy' rating on Glacier Bancorp (NYSE:GBCI) and raises the price target from $37 to $39.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:57 pm

JAZZ

B of A Securities analyst Jason Gerberry maintains a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and raises the price target from $204 to $217.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 4:55 pm